Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 on Cardiac Repolarization in Healthy Subjects
NCT07594847Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of conveglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Huadong Medicine. Primary endpoint: Correlation between HDM1002 Plasma Concentration and ΔΔQTc. Started Mar 2026; status: recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07594847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594847.